Mihai Hârza

Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

Robert J. Motzer, Dmitry Nosov, Timothy Eisen et al. · Journal of Clinical Oncology · 2013 · 443 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer

Cora N. Sternberg, Andrew J. Armstrong, Siobhan Ng et al. · Journal of Clinical Oncology · 2016 · 101 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial.

Robert J. Motzer, Dmitry Nosov, Tim Eisen et al. · Journal of Clinical Oncology · 2012 · 95 citations

Medicine, Oncology, Pharmacology +17

A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis

Robert E. Hawkins, Martin Gore, Yaroslav Shparyk et al. · Clinical Cancer Research · 2016 · 37 citations

Medicine, Oncology, Pharmacology +16

Budesonide versus systemic corticosteroids in IgA Nephropathy

Gener Ismail, Bogdan Obrișcă, Roxana Jurubiță et al. · Medicine · 2020 · 30 citations · Full text

Life Sciences, Nephrology, Pharmacotherapy +10